Edmond DE Rothschild Holding S.A. Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Edmond DE Rothschild Holding S.A. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 7.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,106,110 shares of the biopharmaceutical company's stock after selling 163,621 shares during the period. Pfizer makes up about 1.0% of Edmond DE Rothschild Holding S.A.'s portfolio, making the stock its 22nd biggest position. Edmond DE Rothschild Holding S.A.'s holdings in Pfizer were worth $55,875,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in Pfizer during the fourth quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Pfizer in the 4th quarter valued at about $274,694,000. Fisher Asset Management LLC boosted its holdings in Pfizer by 79.5% in the 4th quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock worth $295,760,000 after buying an additional 4,938,209 shares during the last quarter. Finally, Van ECK Associates Corp increased its stake in Pfizer by 28.5% during the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after buying an additional 4,726,549 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reissued a "neutral" rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus target price of $31.92.

Pfizer Trading Down 3.2 %

Shares of NYSE PFE traded down $0.82 during trading on Tuesday, reaching $24.53. The stock had a trading volume of 54,333,514 shares, compared to its average volume of 39,155,961. The business's 50-day moving average price is $26.05 and its 200-day moving average price is $26.88. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $139.09 billion, a P/E ratio of 17.39, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The business's quarterly revenue was up 24.7% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.